OTV

OTV, based in Herzliya and previously known as Olive Tree Ventures, is a digital health-focused growth fund whose distinguishing feature is its bridge between Israeli technology companies and large Asian and US markets. The fund was rebuilt around a concentrated digital health and health-IT mandate, and its investment activity reflects that focus. Companies in the portfolio tend to be high-performance software businesses operating in telemedicine, clinical decision support, remote monitoring, and AI-enabled care platforms.

The thesis assumes that Israeli founders build globally relevant healthcare software but often need structured help reaching scale outside Israel. OTV provides that, particularly into Asian markets where conventional Western VCs lack networks and into the US where commercial execution is harder than the local pitch suggests. AI is treated as a standard enabling layer, and the fund favors companies where the data advantage and clinical evidence base are strong rather than ones where AI is decorative.

Check sizes range from $1M to $5M at entry, deployed primarily at Series A and Series B. The fund participates in larger rounds with partners and holds reserves for follow-on. Geography of origin is principally Israel, with the company’s commercial center of gravity expected to be the US, selected European markets, or Asia depending on the indication. Syndicate relationships span Israeli, US, and Asian investors, which matters when later rounds require capital from regions outside conventional venture circles.

The team carries a mix of healthcare investing and operational backgrounds, supplemented by relationships into Asian healthcare systems, payers, and corporate strategics built up over the firm’s history. Board engagement is standard at Series A and Series B, and the fund is generally hands-on around international expansion, payer and provider commercial motion, and downstream financing strategy.

Founders should approach OTV when commercial traction has emerged, regulatory work is mature or near mature, and the next chapter requires geographic expansion or a more sophisticated payer and channel strategy. Introductions through Israeli and US healthcare VCs, portfolio CEOs, or strategic operators in the digital health space are the most efficient route. The right moment to engage is six to twelve months before a planned Series A or B raise, with enough time for the fund to track progress, evaluate metrics, and develop conviction. Companies still in the early product or pre-commercial phase are typically better served by seed-stage funds. Pure consumer wellness without a clinical or payer angle, traditional medical devices, and biotech are not core to OTV’s mandate. For founders building Israeli digital health software with global ambition who want a partner structurally connected to Asian markets and US commercial execution, OTV is one of the most distinctive options available.